Skip to content Skip to sidebar Skip to footer
Subscribe Now
BMS
News

BMS’ Augtyro (Repotrectinib) Gains the CHMP’s Positive Opinion to Treat Advanced ROS1+ NSCLC and NTRK+ Solid Tumors 

Shots:    The CHMP has granted positive opinion to repotrectinib for treating ROS1+ advanced NSCLC in adults and NTRK+ advanced solid tumors in patients (≥12yrs.), with the EC’s decision anticipated in Jan 2025 Opinion was based on P-I/II (TRIDENT-1 & CARE) trials, with TRIDENT-1 assessing repotrectinib in advanced solid tumors (NSCLC and tumors with ROS1 &…
November 15, 20240Comments

Read more

ThoughtSpot_Saurabh Chaubey2
THOUGHTSPOT

Bridging the Biopharma Gap with Consulting Firms

Shots: In the extremely competitive biopharma industry, it’s never too soon to learn about the players who help biopharma companies understand the evolving landscape of the biopharma industry Consulting firms are instrumental in guiding biopharma companies in decision-making, understanding the regulatory challenges, and market dynamics This article from PharmaShots unfolds the benefits of onboarding a…
November 13, 20240Comments

Read more

Spotlight Interview_UWE Tigor_JED Litwinuik
SPOTLIGHT

CXO Talks: Jed Litwiniuk & Uwe Tigör from Auxilius Pharma in a Riveting Dialogue Exchange with PharmaShots

In this fifth episode of our recently launched CXO Talks, we spoke with a distinguished panel of speakers from Auxilius Pharma, Jed Litwiniuk, the CEO, and Uwe Tigör, the CMO of the company. Auxilius Pharma is an emerging specialized pharma company aimed at developing, optimizing, and delivering well-established medications internationally.  Jed & Uwe walked memory…
November 11, 20240Comments

Read more

ThoughtSpot_Yan Liao
THOUGHTSPOT

The Role of CCL17 in Immune Regulation: Unlocking New Therapeutic Possibilities

The CCL17 gene, a key player in the human immune system, has garnered significant attention for its role in disease regulation. This chemokine gene is pivotal in mediating immune responses, acting as a messenger that guides immune cells to sites of inflammation. Understanding its function and regulation is essential for unraveling the complexities of immune-related…
November 8, 20240Comments

Read more

Viewpoints_Jason Lerner
VIEWPOINTS

Transcending Epilepsy Care: Jason Lerner from Biohaven in an Enlightening Dialogue Exchange with PharmaShots

Shots: Epilepsy affects around 1.5 million people in the US and 50 million globally. With approximately 40% of epilepsy patients being drug-resistant, there is an urgent need for innovative therapies Today, at PharmaShots we have Dr. Jason Lerner from Biohaven shedding light on BHV-7000, an investigational anti-seizure treatment and selective activator of potassium channels in…
November 6, 20240Comments

Read more